Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$1.28
$0.75
$26.18
$7.26M1.27811,695 shs119,800 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$1.13
+4.6%
$0.99
$0.81
$3.02
$45.20M2.791.08 million shs1.90 million shs
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
$15.13
$14.82
$11.53
$15.89
$223.77M1.45396,929 shsN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$0.88
$0.88
$0.62
$1.47
$26.53M1.221,000 shsN/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
0.00%+18.82%+13.44%+1.80%-23.13%
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.077 of 5 stars
3.53.00.00.03.30.00.0
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00
N/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
3.00
Buy$9.00696.46% Upside
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
0.00
N/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MACK, ADMP, PXSLY, and ITRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$9.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$4.76M0.00N/AN/A($1.26) per share0.00
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.15) per shareN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$8.75M3.03N/AN/A$0.04 per share22.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.99N/AN/AN/AN/A-71.37%8/13/2025 (Estimated)
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
-$1.18M$13.871.09N/AN/A-1.93%-1.78%N/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
-$9.36MN/A0.00N/AN/AN/AN/AN/A

Latest MACK, ADMP, PXSLY, and ITRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.14-$0.14N/A-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/A
0.23
0.19
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
3.72
3.58
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
N/A
10.78
10.78
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
2.82
3.31
2.92

Institutional Ownership

CompanyInstitutional Ownership
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
38.55%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
63.97%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
119.36 million9.24 millionOptionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1040.00 million36.32 millionNot Optionable
Merrimack Pharmaceuticals, Inc. stock logo
MACK
Merrimack Pharmaceuticals
42614.79 million10.27 millionOptionable
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
6930.15 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adamis Pharmaceuticals stock logo

Adamis Pharmaceuticals NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$1.13 +0.05 (+4.63%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.20 +0.07 (+5.75%)
As of 07/11/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Merrimack Pharmaceuticals stock logo

Merrimack Pharmaceuticals NASDAQ:MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Pharmaxis stock logo

Pharmaxis OTCMKTS:PXSLY

$0.88 0.00 (0.00%)
As of 06/8/2021

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.